Australian and NCCN guidelines state that while anti-EGFR therapy is recommended in left-sided CRC, the recommendation for anti-EGFR therapy in right-sided mCRC should be individualised on a case-by-case basis, given its lack of proven benefit [7,9]. The gene discussed is EGFR; the disease is colorectal carcinoma.